Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.60 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.49 |
| ▸ | LPL | P06858 | 1/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.49 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.47 |
| ▸ | LIPC | P11150 | 2/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | PTGES | O14684 | 1/20 | 0.45 |
| ▸ | FABP4 | P15090 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954954 | 0.88 | SCN8A (0.58) | SCN8ASCN10APTGER1PTGDR2LIPG | |
| SCHEMBL954415 | 0.83 | SCN8A (0.53) | SCN8ASCN10APTGER1PTGDR2PARP10 | |
| SCHEMBL955835 | 0.80 | SCN8A (0.48) | SCN8ASCN10APTGER1PTGDR2LIPG | |
| SCHEMBL955834 | 0.80 | SCN8A (0.48) | SCN8ASCN10APTGER1PTGDR2LIPG | |
| SCHEMBL3784235 | 0.78 | KDM4E (0.63) | SCN8ASCN10AKDM4EALDH1A1HPGD | |
| SCHEMBL2924380 | 0.76 | KDM4E (0.61) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL954464 | 0.76 | HSD17B10 (0.66) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL1388095 | 0.76 | FAAH (0.60) | KDM4EALDH1A1PTGDR2PARP10PARP15 | |
| SCHEMBL22809676 | 0.76 | SCN8A (0.48) | SCN8ASCN10APTGER1PTGDR2LIPG | |
| SCHEMBL20325949 | 0.76 | PARP10 (0.57) | SCN8ASCN10AHPGDPARP10PARP15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2238105-B1 | NOVEL COMPOUNDS AS VANILLOID RECEPTOR ANTAGONISTS | AMOREPACIFIC CORP (KR) | 2014-04-16 | — | — | EP | disclosed |
| US-20140011881-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2014-01-09 | — | — | US | disclosed |
| US-8557872-B2 | Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same | AMOREPACIFIC CORPORATION (KR) | 2013-10-15 | — | — | US | disclosed |
| US-20110015230-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2011-01-20 | — | — | US | disclosed |
| EP-2238105-A2 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Amorepacific Corporation (KR) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009096701-A2 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011881-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TRPV1, TRPA1, TRPV2 | SCN8A 303/4885SCN10A 209/4885KDM4E 4650/4885 |
| US-20110015230-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TRPV1, TRPA1, TRPV2 | SCN8A 303/4885SCN10A 209/4885KDM4E 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.